A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

NCT03666728 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped changes in the R\&D strategy

Conditions

Lung Neoplasms

Interventions

DRUG: SHR-1210
DRUG: BP102

Sponsor

Jiangsu HengRui Medicine Co., Ltd.